Featured

T-RAP – a new tool for predicting TCR-pMHC reactivity

Predicting TCR-pMHC reactivity is useful for a variety of immunotherapy research tasks, including identifying relevant neoantigens and developing vaccines. In work recently published in Immunity, Messemaker et al. developed a TCR rapid assembly...

Tumor-targeted IL-10 synergizes with IL-2 to enhance antitumor immunity while minimizing immune-related adverse events

By analyzing TGCA data and performing tumor modeling in IL-10R KO mice, Sun et al. showed that concurrent IL-10 and high IL-2 signaling correlated with improved tumor control. Combining intratumoral i...

Senescence-directed nanotherapy ameliorates fibrosis and overcomes immune exclusion in cancer

Hinterleitner, Barthet, and Goldberg et al. showed that senescent-like cells in fibrotic human and mouse tissues expressed P-selectin, and the team developed fucoidan-based senescence-modulating nanop...

Computational design of optimized and preferentially paired human TCR constant regions for improved T cell function

Using a computational strategy, Radman et al. mutated the constant and transmembrane regions of the MART-1 DMF4 TCR α/β chains to reduce mispairing and improve expression. TCR variants were found that...

Metastasis enables immunogenicity through migrasome-mediated antigen release

Jiang and He et al. show that during vascular migration, circulating tumor cells release antigen-enriched migrasomes, which stimulate anti-metastatic immunity. Migrasomes contained cancer-testis and m...

See all for this week

Previous Digests

CD4 takes the lead: IL‑21 synergizes with KRAS inhibition for durable PDAC control

September 30, 2026

Pancreatic ductal adenocarcinoma (PDAC) has proven to be a challenge for immunotherapy treatment. KRAS inhibitors have shown efficacy in PDAC, but acquired resistance is common. In a recent publication in Cell, Qiang, Hoffman, Chun, et al. investigated whether combinations...

PLA2G2D: A new checkpoint lymph node macrophage

September 23, 2026

Tumor-draining lymph nodes (tdLNs) are critical sites for both antitumor immunity and tumor metastasis. To better understand what influences these events, van Krimpen and Huang et al. performed spatial proteogenomics studies on tdLNs from patients with melanoma. In addition...

Affinity matters for novel IL-2 variant that synergizes with other immunotherapies

September 16, 2026

Antitumor IL-2 treatment comes with challenges regarding toxicity and unintended Treg activation. To overcome these challenges, various approaches to engineer IL-2 variants (IL-2var) have been developed. In a recent Science Advances publication, Vormehr et al. reported preclinical data on...

See More Digests

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

Donate to support researchers

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ute Burkhardt

Ed Fritsch

Lauren Hitchings

Gaëlle Llambi

Maartje Wouters

Alex Najibi

Katherine J. Turner

Stan Wolf

Paula Hochman

Shishir Pant

Nathan Suek

Morgan Janes

More About Us

TESTIMONIALS

I'm a big fan of ACIR. I enjoy their weekly newsletters with clear, concise, and insightful summaries, complemented by excellent images. I've even used the images in some of my presentations to explain complex cancer immunotherapy findings. In our rapidly evolving field, their reliable and well-curated updates are invaluable.

— Carl H. June, MD

Richard W. Vague Professor in Immunotherapy; Professor of PL&M; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy; University of Pennsylvania Perelman School of Medicine. (Supporter since 2025).

Testimonials